Sequenom (FRA:QNMA) LT-Debt-to-Total-Asset : 1.31 (As of Jun. 2016)

View and export this data going back to . Start your Free Trial

What is Sequenom LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sequenom's long-term debt to total assests ratio for the quarter that ended in Jun. 2016 was 1.31.

Sequenom's long-term debt to total assets ratio increased from Jun. 2015 (0.98) to Jun. 2016 (1.31). It may suggest that Sequenom is progressively becoming more dependent on debt to grow their business.

Sequenom LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sequenom's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequenom LT-Debt-to-Total-Asset Chart

Sequenom Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.13

0.52

0.97

0.84

1.13

Sequenom Quarterly Data
	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.98	1.04	1.13	1.27	1.31

Sequenom LT-Debt-to-Total-Asset Calculation

Sequenom's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as

LT Debt to Total Assets (A: Dec. 2015 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2015 )	/	Total Assets (A: Dec. 2015 )
	=	123.404	/	109.042
	=	1.13

Sequenom's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2016 is calculated as

LT Debt to Total Assets (Q: Jun. 2016 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2016 )	/	Total Assets (Q: Jun. 2016 )
	=	113.745	/	86.623
	=	1.31

Sequenom (FRA:QNMA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sequenom LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sequenom's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sequenom (FRA:QNMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sequenom Inc (FRA:QNMA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.sequenom.com

Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.

Sequenom (FRA:QNMA) Headlines

No Headlines